Oncofetal Antigens in Ovarian Cyst Fluids

1984 ◽  
Vol 18 (3) ◽  
pp. 117-121 ◽  
Author(s):  
D.H. Kraly ◽  
S.H. Koh ◽  
D.L. Hay ◽  
M.N. Cauchi
Tumor Biology ◽  
1987 ◽  
Vol 8 (4) ◽  
pp. 230-232 ◽  
Author(s):  
Gábor Than ◽  
Markku Seppälä ◽  
Imre Csaba ◽  
Koichi Iino ◽  
Volkert Briese

Author(s):  
R Halperin ◽  
M Pansky ◽  
Z Vaknin ◽  
S Zehavi ◽  
I Bukovsky ◽  
...  

2012 ◽  
Vol 125 ◽  
pp. S102-S103
Author(s):  
I. Podzielinski ◽  
B. Saunders ◽  
K. Kimbler ◽  
K. Ferguson ◽  
A. Branscum ◽  
...  
Keyword(s):  

1988 ◽  
Vol 34 (9) ◽  
pp. 1853-1857 ◽  
Author(s):  
J T Wu ◽  
T Miya ◽  
J A Knight ◽  
D P Knight

Abstract We found that ovarian cyst fluids contained carcinoembryonic antigen (CEA) and CA 19-9 and CA 125 tumor markers. However, only the ratio of CA 125 to CEA concentrations provided sufficient specificity to differentiate serous from mucinous cysts. For CEA measurement, our results suggested the use of a monoclonal CEA kit. When CEA was determined with a Hybritech monoclonal CEA kit, all ratios in mucinous ovarian cysts were less than 10 and most of the ratios were greater than 1000 in serous ovarian cysts. We also found that the ratio of CA 125 to CEA in serum could be used to differentiate ovarian from nonovarian malignant diseases when both sera contain increased CA 125 concentrations. The nonovarian malignancies consisted of colorectal, breast, lung, and pancreatic carcinomas. The mean ratio for serum from patients with nonovarian cancers was 0.94 (n = 19); for ovarian-cancer patients (n = 45), 916. Therefore, determining this ratio will greatly improve the specificity of the CA 125 test for ovarian cancer.


eLife ◽  
2016 ◽  
Vol 5 ◽  
Author(s):  
Yuxuan Wang ◽  
Karin Sundfeldt ◽  
Constantina Mateoiu ◽  
Ie-Ming Shih ◽  
Robert J Kurman ◽  
...  

We determined whether the mutations found in ovarian cancers could be identified in the patients' ovarian cyst fluids. Tumor-specific mutations were detectable in the cyst fluids of 19 of 23 (83%) borderline tumors, 10 of 13 (77%) type I cancers, and 18 of 18 (100%) type II cancers. In contrast, no mutations were found in the cyst fluids of 18 patients with benign tumors or non-neoplastic cysts. Though large, prospective studies are needed to demonstrate the safety and clinical utility of this approach, our results suggest that the genetic evaluation of cyst fluids might be able to inform the management of the large number of women with these lesions.


1955 ◽  
Vol 60 (3) ◽  
pp. 428-436 ◽  
Author(s):  
R. A. Gibbons ◽  
W. T. J. Morgan ◽  
Marion Gibbons
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document